ECSP034639A - Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos - Google Patents

Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos

Info

Publication number
ECSP034639A
ECSP034639A EC2003004639A ECSP034639A ECSP034639A EC SP034639 A ECSP034639 A EC SP034639A EC 2003004639 A EC2003004639 A EC 2003004639A EC SP034639 A ECSP034639 A EC SP034639A EC SP034639 A ECSP034639 A EC SP034639A
Authority
EC
Ecuador
Prior art keywords
pharmacologically active
pharmaceutical compositions
active agent
agent
oral supply
Prior art date
Application number
EC2003004639A
Other languages
English (en)
Inventor
Joseph M Ault
Moise Azria
Simon David Bateman
Joseph Sikora
Gregory Sparta
Rebecca Fai-Ying Yang
Jie Xiao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP034639A publication Critical patent/ECSP034639A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se dan a conocer composiciones farmacéuticas sólidas adecuadas para el suministro oral de agentes farmacológica mente activos, por ejemplo péptidos, las cuales comprenden una cantidad terapéuticamente efectiva de un agente farmacológica mente activo, una crospovidona o providona, y un agente de suministro para este agente farmacológica mente activo,. Las composiciones proporcionan una excelente biodisponiblidad oral de los agentes farmacológica mente activos, en particular calcitonina
EC2003004639A 2000-12-06 2003-06-04 Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos ECSP034639A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25172900P 2000-12-06 2000-12-06

Publications (1)

Publication Number Publication Date
ECSP034639A true ECSP034639A (es) 2003-07-25

Family

ID=22953160

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004639A ECSP034639A (es) 2000-12-06 2003-06-04 Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos

Country Status (26)

Country Link
US (1) US7049283B2 (es)
EP (1) EP1341526B1 (es)
JP (2) JP4898078B2 (es)
KR (1) KR100847695B1 (es)
CN (1) CN1304048C (es)
AT (1) ATE513541T1 (es)
AU (2) AU2002234547B2 (es)
BR (2) BRPI0115965B1 (es)
CA (1) CA2436599C (es)
CY (1) CY1112562T1 (es)
CZ (1) CZ305418B6 (es)
DK (1) DK1341526T3 (es)
EC (1) ECSP034639A (es)
ES (1) ES2367009T3 (es)
HU (1) HU230632B1 (es)
IL (2) IL155992A0 (es)
MX (1) MXPA03005096A (es)
NO (1) NO332936B1 (es)
NZ (1) NZ526196A (es)
PL (1) PL209703B1 (es)
PT (1) PT1341526E (es)
RU (1) RU2287999C2 (es)
SI (1) SI1341526T1 (es)
SK (1) SK287613B6 (es)
WO (1) WO2002045754A2 (es)
ZA (1) ZA200304295B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
JP5073153B2 (ja) * 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
AR040737A1 (es) * 2002-08-01 2005-04-20 Novartis Ag Administracion oral de calcitonina
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
MXPA06000446A (es) * 2003-07-11 2006-04-07 Novartis Ag Composiciones farmaceuticas de dosis oral que comprenden un agente de distribucion en forma micronizada.
PT2316473E (pt) * 2003-07-23 2013-09-20 Novartis Ag Utilização de calcitonina na osteoartrite
AR045637A1 (es) * 2003-09-12 2005-11-02 Amgen Inc Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio
BRPI0510906A (pt) * 2004-05-19 2007-11-06 Emisphere Tech Inc composição farmacêutica tópica, composição para administração tópica e seu uso
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
PE20070548A1 (es) 2005-09-19 2007-07-12 Emisphere Tech Inc Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
WO2007095716A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EP2049137A4 (en) * 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
EP2059260B1 (en) * 2006-08-31 2013-06-19 Novartis AG Pharmaceutical compositions comprising hGH for oral delivery
CA2572004A1 (en) * 2006-12-08 2008-06-08 Bernard Charles Sherman Tablets comprising entacapone and crospovidone
WO2008109385A2 (en) * 2007-03-02 2008-09-12 Novartis Ag Oral administration of a calcitonin
US8022048B2 (en) 2007-11-02 2011-09-20 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
EP2405934B1 (en) * 2009-03-12 2014-03-26 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
AU2011264808B2 (en) * 2010-06-09 2015-01-22 Emisphere Technologies, Inc. Oral iron deficiency therapy
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
UA121890C2 (uk) * 2015-07-08 2020-08-10 Рісерч Енд Бізнес Фаундейшн Сонгюнгван Юніверсіті Похідні карбоксамідопіролідину та способи їхнього отримання та застосування
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
CN107080739A (zh) * 2017-04-17 2017-08-22 深圳市泛谷药业股份有限公司 一种用于口服给药的固体快速释放布南色林片及其制备方法
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド 共結晶形エフィナコナゾール、及びその製造方法
KR102301743B1 (ko) * 2020-12-29 2021-09-13 대봉엘에스 주식회사 에피나코나졸 경구용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015633A (en) 1987-04-27 1991-05-14 E. R. Squibb & Sons, Inc. Method for inhibiting loss of cognitive functions employing an ace inhibitor
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5002771A (en) 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
IT1238072B (it) 1990-01-19 1993-07-03 Sclavo Spa Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
JPH052771A (ja) * 1991-06-25 1993-01-08 Pioneer Electron Corp 光記録媒体
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
PT800384E (pt) 1994-12-14 2001-06-29 Enbalt Trading Ltd Metodo para a preparacao de um comprimido farmaceutico
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
ATE383169T1 (de) 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GEP20043260B (en) 1998-03-16 2004-06-25 Nectar Therapeutics Aerosolized Active Agent Delivery and Device for Realization Thereof
AU3574500A (en) 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
WO2000059480A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents

Also Published As

Publication number Publication date
NO20032511L (no) 2003-06-03
PT1341526E (pt) 2011-09-01
IL155992A0 (en) 2003-12-23
WO2002045754A2 (en) 2002-06-13
PL362247A1 (en) 2004-10-18
BRPI0115965B1 (pt) 2017-09-26
SK6882003A3 (en) 2004-01-08
ES2367009T3 (es) 2011-10-27
CZ305418B6 (cs) 2015-09-09
CY1112562T1 (el) 2016-02-10
CA2436599C (en) 2011-01-25
HU230632B1 (hu) 2017-05-29
CN1479612A (zh) 2004-03-03
EP1341526A2 (en) 2003-09-10
MXPA03005096A (es) 2003-09-05
BR0115965A (pt) 2003-10-28
JP4898078B2 (ja) 2012-03-14
NO20032511D0 (no) 2003-06-03
DK1341526T3 (da) 2011-10-03
ZA200304295B (en) 2004-05-10
KR100847695B1 (ko) 2008-07-23
RU2287999C2 (ru) 2006-11-27
SI1341526T1 (sl) 2011-10-28
CZ20031566A3 (cs) 2003-09-17
HUP0302319A3 (en) 2013-04-29
PL209703B1 (pl) 2011-10-31
NO332936B1 (no) 2013-02-04
HUP0302319A2 (hu) 2003-11-28
WO2002045754A3 (en) 2003-01-03
IL155992A (en) 2008-04-13
US7049283B2 (en) 2006-05-23
KR20040018309A (ko) 2004-03-03
JP2009185052A (ja) 2009-08-20
CN1304048C (zh) 2007-03-14
NZ526196A (en) 2005-01-28
ATE513541T1 (de) 2011-07-15
EP1341526B1 (en) 2011-06-22
JP2004515480A (ja) 2004-05-27
AU3454702A (en) 2002-06-18
US20020123459A1 (en) 2002-09-05
SK287613B6 (sk) 2011-04-05
CA2436599A1 (en) 2002-06-13
HK1059565A1 (en) 2004-07-09
AU2002234547B2 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
NO20032511L (no) Farmasöytiske sammensetninger for oral tilförsel av farmakologisk aktive midler
BR9914251A (pt) Formulações orais de liberação sustentada
ITMI20001173A0 (it) Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva.
DE602004023093D1 (de) N mit einem abgabemittel in mikronisierter form
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
BRPI0113331B8 (pt) derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
WO2001022791A3 (en) Controlled release compositions comprising nimesulide
AR044775A1 (es) Composiciones farmaceuticas de atorvastatina
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
IT1255460B (it) Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive
DK1608349T3 (da) Oralt tilförselssystem omfattende et antibakterielt og et antiinflammatorisk middel
BR0112847A (pt) Uso de uma forma de dosagem sólida
ECSP014082A (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos
ECSP003685A (es) Formulaciones orales de liberacion controlada
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
FR2798288B1 (fr) Compositions vaccinales destinees a une administration par voie muqueuse
NO20034873D0 (no) Bredspektret 2-(amino)-benzoxazolsulfonamid HIV proteasehemmere
GT199700112A (es) Nuevas microesferas farmaceuticas para administracion oral.
GT200100223A (es) Composiciones hidroliticamente inestables.
AR020867A1 (es) Agente terapeutico para la hipercalcemia resistente a las drogas